Desipramine dibudinate | CAS# 62265-06-9 (dibudinate) | tricyclic dibenzazepine

MedKoo Cat#: 413573 | Name: Desipramine dibudinate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Desipramine dibudinate is a tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.

Chemical Structure

Desipramine dibudinate

CAS#62265-06-9 (dibudinate)

Theoretical Analysis

MedKoo Cat#: 413573

Name: Desipramine dibudinate

CAS#: 62265-06-9 (dibudinate)

Chemical Formula: C36H46N2O6S2

Exact Mass: 666.2797

Molecular Weight: 666.89

Elemental Analysis: C, 64.84; H, 6.95; N, 4.20; O, 14.39; S, 9.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

34289-31-1 (trifluoroacetate) 58-28-6 (HCl) 50-47-5 (free base) 62265-06-9 (dibudinate)

Synonym

Desipramine dibudinate; Nebril; UNII-ZR57B065D1

IUPAC/Chemical Name

5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-, 2,6-bis(1,1-dimethylethyl)-1,5-naphthalenedisulfonate (1:1)

InChi Key

AMLRZIZSGSCSHZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H22N2.C18H24O6S2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20;1-17(2,3)13-9-7-12-11(15(13)25(19,20)21)8-10-14(18(4,5)6)16(12)26(22,23)24/h2-5,7-10,19H,6,11-14H2,1H3;7-10H,1-6H3,(H,19,20,21)(H,22,23,24)

SMILES Code

CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31.O=S(C4=C5C=CC(C(C)(C)C)=C(S(=O)(O)=O)C5=CC=C4C(C)(C)C)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 666.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992 May 7;326(19):1250-6. doi: 10.1056/NEJM199205073261904. PMID: 1560801. 2: Branco-de-Almeida LS, Franco GCN, Castro ML, Vieira MS, Galvão-Moreira LV, Cortelli SC, Anbinder AL, Kawai T, Rosalen PL. Protective effects of desipramine on alveolar bone in experimental periodontitis. J Periodontol. 2020 Dec;91(12):1694-1703. doi: 10.1002/JPER.19-0569. Epub 2020 Jun 5. PMID: 32294250. 3: Janowsky DS, Byerley B. Desipramine: an overview. J Clin Psychiatry. 1984 Oct;45(10 Pt 2):3-9. PMID: 6384207. 4: Desipramine. Med Lett Drugs Ther. 1965 May 21;7(11):44. PMID: 5826748. 5: Nelson JC. Use of desipramine in depressed inpatients. J Clin Psychiatry. 1984 Oct;45(10 Pt 2):10-6. PMID: 6384205. 6: Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet. 1990 May;18(5):346-64. doi: 10.2165/00003088-199018050-00002. PMID: 2185906. 7: Ghanizadeh A. A systematic review of the efficacy and safety of desipramine for treating ADHD. Curr Drug Saf. 2013 Jul;8(3):169-74. doi: 10.2174/15748863113089990029. PMID: 23914752. 8: Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, Gracely RH, Dubner R. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 1990 Mar;47(3):305-12. doi: 10.1038/clpt.1990.33. PMID: 2178851. 9: Leonard BE. A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review. Int Clin Psychopharmacol. 1987 Oct;2(4):281-97. doi: 10.1097/00004850-198710000-00001. PMID: 2891742. 10: Werry JS. The safety of desipramine. J Am Acad Child Adolesc Psychiatry. 1994 May;33(4):588-91. doi: 10.1097/00004583-199405000-00018. PMID: 8005913.